{
    "clinical_study": {
        "@rank": "68983", 
        "acronym": "COMBINE-II", 
        "arm_group": {
            "arm_group_label": "Primary Cohort", 
            "arm_group_type": "Experimental", 
            "description": "Main cohort; treatment Arm with Pantheris Atherectomy System"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the safety and effectiveness of the Pantheris System to perform atherectomy\n      while using directional visualization and imaging as an adjunct to fluoroscopy to aid\n      removal of plaque from diseased lower extremity arteries."
        }, 
        "brief_title": "Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral Arterial Disease", 
        "condition_browse": {
            "mesh_term": [
                "Peripheral Arterial Disease", 
                "Peripheral Vascular Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age \u2265 18 years old.\n\n          2. Patient is a candidate for percutaneous intervention for peripheral vascular disease\n             in the legs.\n\n          3. Patient is willing and able to give informed consent\n\n          4. Documented symptomatic atherosclerotic peripheral vascular disease Rutherford\n             Classification 2-5.\n\n          5. Reference vessel lumen proximal to target lesion >3.0 mm in diameter by visual\n             estimation.\n\n          6. Subject has de novo target lesion(s) with stenosis >70% by visual estimation distal\n             to the profunda femoral artery.  No more than 2 lesions may be treated with the\n             Pantheris device.\n\n          7. Target lesion length <10 cm if target lesion >70% and <99% stenosed.  If target\n             lesion a chronic total occlusion (99-100% stenosed), target lesion length <4 cm.\n\n          8. Patient is capable of meeting requirements and be present at the follow-up clinic\n             visits at 30 days.\n\n          9. At least one patent tibial run-off vessel at baseline.  -\n\n        Exclusion Criteria:\n\n          1. Subject is pregnant or breast feeding.\n\n          2. Rutherford Class 0 to 1 (asymptomatic and mild claudication).\n\n          3. Rutherford Class 6 (critical limb ischemia).\n\n          4. Severe calcification of the target lesion.\n\n          5. Target lesion with any type of stent or graft.\n\n          6. Target lesion in the iliac artery.\n\n          7. Target lesion stenosis <70%.\n\n          8. Subjects with significant (>70%) occlusive lesions proximal to the target lesion not\n             successfully treated during the index procedure (upstream disease) and prior to\n             treatment of the target lesion.\n\n          9. Endovascular or surgical procedure performed on the index limb less than or equal to\n             30 days prior to the index procedure.\n\n         10. Planned endovascular or surgical procedure 30 days after the index procedure.\n\n         11. Lesion in the contralateral limb requiring intervention during the index procedure or\n             within 30 days of the index procedure.\n\n         12. Subjects with active infections whether they are being currently treated or not.\n\n         13. Hemodialysis or GFR <30 mL/min or creatinine level >2.5mg/dL.\n\n         14. Evidence or history of intracranial or gastrointestinal bleeding, intracranial\n             aneurysm, myocardial infarction or stroke within the past 2 months.\n\n         15. Evidence or history of aneurysmal target vessel within the past 2 months.\n\n         16. History of severe trauma, fracture, major surgery or biopsy of a parenchymal organ\n             within the past 14 days.\n\n         17. Known allergy to contrast agents or medications used to perform endovascular\n             intervention that cannot be adequately pre-treated.\n\n         18. Subjects in whom anti-platelet, anticoagulant, or thrombolytic therapy is\n             contraindicated.\n\n         19. History of heparin-induced thrombocytopenia (HIT).\n\n         20. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with\n             platelet count less than 125,000/mm2 , known coagulopathy, or INR >1.5.\n\n         21. Any thrombolytic therapy within 2 weeks of the index procedure.\n\n         22. Any clinical and/or angiographic complication attributed to the use of another device\n             prior to the insertion of the Pantheris into the subject.\n\n         23. Subjects or their legal guardians who have not or will not sign the Informed Consent.\n\n         24. Subjects who are unwilling or unable to comply with the follow-up study requirements.\n\n         25. Participation in any study of an investigational device, medication, biologic or\n             other agent within 30 days prior to enrollment that is either a cardiovascular study\n             or could, in the judgment of the investigator, affect the results of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02126540", 
            "org_study_id": "P0638"
        }, 
        "intervention": {
            "arm_group_label": "Primary Cohort", 
            "description": "Treatment device in primary cohort arm; OCT image guided directional atherectomy", 
            "intervention_name": "Pantheris Atherectomy System", 
            "intervention_type": "Device", 
            "other_name": "Pantheris"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Peripheral Arterial Disease", 
            "Atherectomy", 
            "Optical Coherence Tomography"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Auckland", 
                    "country": "New Zealand", 
                    "zip": "1023"
                }, 
                "name": "Auckland City Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Andrew Holden, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Andrew Hill, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "New Zealand"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Non-randomized, Multi-center Feasibility Trial of the Avinger Pantheris System, an Atherectomy Device That Provides Directional Visualization and Imaging While Removing Plaque in Diseased Lower Extremity Arteries", 
        "overall_contact": {
            "email": "AndrewH@adhb.govt.nz", 
            "last_name": "Andrew Holden, MD", 
            "phone": "(09) 3074949", 
            "phone_ext": "23905"
        }, 
        "overall_contact_backup": {
            "email": "ashou@adhb.govt.nz", 
            "last_name": "Ann Zhou", 
            "phone": "(09) 3074949", 
            "phone_ext": "21976"
        }, 
        "overall_official": {
            "affiliation": "Auckland City Hospital", 
            "last_name": "Andreq Holden, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "New Zealand: Ethics Committee", 
                "New Zealand: Health and Disability Ethics Committees"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The primary safety endpoint is defined as freedom from major adverse events (MAE) through 30 day follow-up:\nClinically driven target lesion revascularization (TLR)\nMyocardial infarction (MI)\nCardiovascular related deaths\nUnplanned, major index limb amputation\nDevice Related Events:\nClinically Significant Perforations\nClinically Significant Dissections\nClinically Significant Embolus\nPseudoaneurysm", 
                "measure": "Primary Safety Endpoint", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0 through Day 30"
            }, 
            {
                "description": "The primary efficacy endpoint of technical success is defined as the percent of target lesions that has a residual diameter stenosis <50% post the Pantheris device alone as assessed by an independent review at the time of treatment using quantitative angiography or visual estimate.", 
                "measure": "Primary Effectiveness Endpoint", 
                "safety_issue": "No", 
                "time_frame": "Day 0"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02126540"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Freedom from procedural emboli, defined as a new occlusion of any visualized runoff vessel which cannot be reversed with an intravascular vasodilator.", 
                "measure": "Secondary Safety Endpoint", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0"
            }, 
            {
                "description": "Procedural success defined as the percent of target lesions that have residual diameter stenosis < 30% post-Pantheris and any other adjunctive therapy.", 
                "measure": "Secondary Effectiveness Endpoint", 
                "safety_issue": "No", 
                "time_frame": "Day 0"
            }, 
            {
                "description": "Ankle-Brachial Index at 30 days", 
                "measure": "Secondary Effectiveness Endpoint", 
                "safety_issue": "No", 
                "time_frame": "Day 30"
            }, 
            {
                "description": "Rutherford Classification at 30 days.", 
                "measure": "Secondary Effectiveness Endpoint", 
                "safety_issue": "No", 
                "time_frame": "Day 30"
            }
        ], 
        "source": "Avinger, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Avinger, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}